'An eye test helped reveal my daughter's tumour'
The mother of a girl diagnosed with a brain tumour so large it distorted the shape of her brain says the ordeal has helped her see the importance of children's eye tests.
Sophie, 35, from Tean in Staffordshire, took her seven-year-old daughter Esmai to the opticians in January 2024 after she complained she could see spots.
They were told there were no problems but a year later Esmai experienced what her mum believed was a "mini seizure".
Sophie took her back to the opticians and was told to go straight to A&E. An MRI scan a few days later revealed the large tumour.
"I don't think anybody really thinks to take their children for eye tests," Sophie said.
"I don't think I would have done unless she said to me she was seeing spots."
She added regular eye checks should be as normal as going to the dentist or hairdressers.
Esmai had a "considerable" ependymoma growing in her brain and is now undergoing radiotherapy.
Her tumour was so big that the central line of her brain had shifted and was curved, her mum said.
"They're quite astounded that she didn't have any other difficulties. No headaches, no weight loss, no sickness, no learning troubles – nothing," she said.
She added the discovery had made her fear for her daughter's life.
"The first thing you think is that your child is going to die. I don't think there are any words to describe [that feeling]."
In February, Esmai underwent seven hours of surgery to remove the tumour at Alder Hey Children's Hospital in Liverpool.
She has now begun an intensive programme of radiotherapy at the Proton Beam Therapy Centre in Manchester.
This involves being pinned to a bed by a special mask before a high-energy beam of protons is sent through her brain, targeting any remaining cancerous cells.
Sophie, Esmai, and Sophie's younger daughter Grace, aged two, have temporarily moved into hospital accommodation while Esmai's treatment is ongoing.
Being away from home means that Sophie cannot work, and a friend has so far raised £3,000 to support her through a crowdfunding appeal.
Follow BBC Stoke & Staffordshire on BBC Sounds, Facebook, X and Instagram.
Could AI help treat brain tumours in children?
The 10-minute test for childhood tumours
Opera star calls for boost to brain tumour research
Alder Hey Children's Hospital
The Proton Bream Therapy Centre
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Families to benefit from £2m support plan
Families in Rotherham are set to benefit from a new £2m plan aimed at improving support for children and parents before problems reach crisis point. At a meeting on Monday, Rotherham Metropolitan Borough Council's cabinet approved the next phase of its Family Help Strategy, which is part of a national push to offer earlier, more joined-up help to struggling families. The money will be used to bring services like social care, education, health and the police closer together, to try and stop families from falling through the cracks. Work on the transformation will begin immediately, with updates expected in the autumn, the council said. The changes aim to make it easier for families to get the right help at the right time, whether that is support with parenting, mental health, school attendance or other challenges, the Local Democracy Service reports. The plan includes the creation of multi-agency teams made up of social workers, education staff, health professionals and others who will work together to offer tailored, practical support before problems escalate. Families will also be more involved in shaping their own support, with a stronger role for extended family networks and a focus on building resilience at home. During the meeting, Victoria Cusworth, cabinet member for children and young people, said: "The funding is targeted at service transformation activity [and] increasing direct delivery of family help. "This is about enabling families to access the right help at the right time, and from the right people, reducing the need for statutory intervention and giving children the best possible start in life." Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North New hub aims to provide support for families Guides on parenting skills available for families Rotherham Council Local Democracy Reporting Service
Yahoo
6 hours ago
- Yahoo
Doctors said my daughter had a tummy bug – then we found out she had just months to live
A mum who pushed doctors for answers after her daughter fell ill with headaches and tummy sickness is urging parents to trust their gut, after what seemed like a common virus turned out to be a rare, inoperable brain tumour. Jackie Dunlop, 38, from Ayrshire, Scotland, first grew concerned in May 2022 when her daughter Ava Nelson, then just 10, began experiencing persistent headaches, dizzy spells and balance issues. At first, doctors believed it was nothing more than a viral infection or tummy bug. Ava underwent blood tests and had multiple visits to her GP and local hospital, but everything came back clear. "To look at her, you wouldn't know anything was wrong," Jackie says. But as the weeks progressed, Ava showed no improvement. As Ava's condition deteriorated, Jackie's instincts told her something wasn't right. "We thought it was a sickness bug," she says. "But three weeks in, I started to worry. Everyone kept putting it down to a viral bug, but I wasn't convinced." Jackie pushed to get Ava admitted to hospital, where more tests were carried out, partly at her insistence. "They agreed to do the blood tests – then Ava started vomiting," she recalls. "She was obviously declining, but the blood tests came back fine. It was then I pushed for a scan." After a month of worsening symptoms, an MRI scan finally revealed that it was not a virus, but a mass on Ava's brain. "They told us Ava had severe pressure on her brain,' Jackie says. "They found a tumour, which caused the pressure." Ava was quickly transferred to the Royal Hospital for Children in Glasgow for emergency surgery to relieve the swelling, but doctors weren't able to remove the tumour due to its location. While the family were devastated, the surgeon told Jackie if she hadn't insisted her daughter go to hospital, Ava likely would have died just a few days later. "They told us if we didn't fight, she'd have been dead within a week because the pressure was that bad," she says. "Four weeks I had been fighting with doctors to get answers." A week later, the biopsy confirmed the family's worst fear – Ava had a high-grade glioblastoma, an aggressive and inoperable brain tumour. She was given just six to 12 months to live. "The hardest part for me was knowing she wasn't going to survive," Jackie says. The family chose not to tell Ava about her prognosis. Instead, Jackie and Ava's dad, Roland, 69, and her family focused on making the time she had left as happy and meaningful as possible. "We were trying to normalise life," she explains. "As a family, we did everything in our willpower to make sure that the time we had left with our warrior was full of fun-filled memories." Ava began 12 weeks of radiotherapy and chemotherapy. The aggressive treatment left her with a feeding tube after the chemotherapy ruptured her stomach. Despite the odds, Ava defied expectations and lived for nearly two years after her diagnosis. In Spring 2023, she moved into Robin House Children's Hospice, where she continued to fight bravely. Ava passed away peacefully on 16 April 2024, surrounded by her mum, dad, and two sisters, aged nine and 17. "They moved her into the rainbow room," Jackie remembers. "She was shy and timid, but sweet and loving. She was the best." Now, Jackie is speaking out to encourage other parents to trust their instincts, no matter what. "Mothers know their child best," she says. "If you feel something is wrong, go get them checked. "If you aren't getting anywhere, stand your ground. Keep pushing until you get the help and answers you need." Additional research: SWNS. If you're worried about your child's symptoms or feel like you're not being listened to, you can go to your practice manager or your GP and ask for a second opinion. The Patients Association, an independent charity, has a free helpline – 0800 345 7115 – where you can get advice about requesting a second opinion, changing your doctor and making a complaint. For help and support on health-related and treatment-related concerns when you're using the NHS, you'll find a Patient Advice and Liaison Service (PALS) in your local hospital. If you're based in Scotland, The Patient Advice and Support Service (PASS) can also help guide you through the process and make sure your concerns are heard. Gliomas – also known as astrocytomas – are the most common type of brain cancer in children and young people. They start in the brain or spinal cord, growing from cells called glial cells, and are generally split into two types. Low-grade gliomas tend to grow more slowly and are diagnosed in around 150 children each year in the UK. High-grade gliomas grow quickly, are harder to treat, and can be fatal. They're also much rarer, with around 30 cases diagnosed in the UK each year. While gliomas are more common in adults, doctors still don't know what causes them in children. Symptoms can vary depending on where the tumour is, but may include: Headaches Tiredness Nausea Vomiting Changes in behaviour or school performance Problems with coordination or movement The NHS recommends calling 111 or visiting your GP if you're concerned, if any of these symptoms last more than three weeks, if your child seems to get worse or if they develop any new symptoms. Read more about brain tumours: Davina McCall makes back-to-work confession after brain tumour surgery (Yahoo Life UK, 7-min read) Like Davina, I had surgery for a benign brain tumour and it changed me forever (Yahoo Life UK, 9-min read) One day I woke up nearly blind, I wish there was more support for people like me (Yahoo Life UK, 6-min read)
Yahoo
10 hours ago
- Yahoo
OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OST-HER2, a Listeria monocytogenes-based immunotherapy, is the first potential new treatment in over 40 years for pediatric osteosarcoma, a rare, aggressive bone cancer that often metastasizes to the lungs, primarily affecting children and adolescents. The therapy has received Orphan, Fast Track and Rare Pediatric Disease Designations from the U.S. Food and Drug Administration (FDA), with a Biologics License Application (BLA) rolling submission targeted to begin in the third quarter of 2025, with potential approval coming as early as year end 2025. "Working with EVERSANA ensures we have the infrastructure, expertise and agility to bring OST-HER2 to patients and families who have long awaited new options without the need to spend significant capital building our own commercial infrastructure," said Paul Romness, CEO of OS Therapies. "By leveraging EVERSANA's flexible integrated commercialization operations and deep oncology experience, we will be able to rapidly and cost-effectively fulfill our mission of transforming the treatment landscape for pediatric metastatic osteosarcoma while judiciously managing pre-BLA costs." EVERSANA will activate its dedicated end-to-end EVERSANA ONCOLOGY Commercialization model, including market access, medical affairs, field deployment, patient services and stakeholder engagement. The fully integrated platform accelerates awareness and access to OST-HER2 among healthcare providers treating osteosarcoma, as well as the potential to treat additional HER2-positive cancers. "We share OS Therapies' relentless commitment to helping patients facing the devastating diagnosis of cancer," said Jim Lang, CEO at EVERSANA. "We've activated the full scale of our commercialization operation and global team of oncology experts to bring this much-needed innovation to market. This product is just the beginning of OS Therapies' impact for patients around the world." The announcement follows OS Therapies' recent issuance of U.S. Patent #12,239,738, securing commercial manufacturing exclusivity for OST-HER2 and its broader Listeria-based immunotherapy platform through 2040. About EVERSANA EVERSANA® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit or connect through LinkedIn and X. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contacts For EVERSANAMatt BraunVice President, Corporate For OS TherapiesJack Doll+1-410-297-7793Irpr@ View original content to download multimedia: SOURCE EVERSANA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
